ConductScience.org, home

Paper61732

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Schein PS and 6 others. Ann Intern Med, 1976. Cited by 396 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Papers, record 61732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/61732

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
PubMed
Journal
Ann Intern Med
PubMed
Year
1976
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
396
iCite
Relative citation ratio, by iCite
17.7
iCite
Revised in PubMed
2019-06-19
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schein PSP S
2DeVita VT JrV T
3Hubbard SS
4Chabner BAB A
5Canellos GPG P
6Berard CC
7Young RCR C

Source PubMed

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BleomycinMajor topic
CyclophosphamideMajor topic
DoxorubicinMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
PrednisoneMajor topic
VincristineMajor topic
Adult
Aged
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Lymphoma
Male
Middle Aged
Remission, Spontaneous

Source PubMed

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 396 citations.

PMIDTitleJournalYearIn PapersSource
42,664,000A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.Blood Adv2026https://conductscience.org/library/papers/42664000PubMed
10,789,823Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.Drug Saf2000https://conductscience.org/library/papers/10789823PubMed
8,471,438Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas.Br J Cancer1993https://conductscience.org/library/papers/8471438PubMed
8,398,705Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.Br J Cancer1993https://conductscience.org/library/papers/8398705PubMed
7,263,762Investigation results of a comparison made between the Kiel and Rappaport classifications of the non-Hodgkin's lymphomas, together with clinical data.J Cancer Res Clin Oncol1981https://conductscience.org/library/papers/7263762PubMed
7,105,385The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7105385PubMed
7,000,112Malignant lymphomas as tumours of the immune system.Br J Cancer1980https://conductscience.org/library/papers/7000112PubMed
6,993,038Is there a role for radiotherapy in localized diffuse lymphomas?Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6993038PubMed
6,934,838DNA content of leukaemic cells in non-Hodgkin's lymphomas of low-grade malignancy. Flow-cytometric and morphological investigations with special regard to hyperploid cells.Blut1980https://conductscience.org/library/papers/6934838PubMed
6,878,096The need for prophylactic treatment to the central nervous system in patients with aggressive non-Hodgkin's lymphoma.Postgrad Med J1983https://conductscience.org/library/papers/6878096PubMed
6,865,273[Non-Hodgkins's lymphomas - current aspects of clinical diagnosis and therapy].Klin Wochenschr1983https://conductscience.org/library/papers/6865273PubMed
6,688,970A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL).Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6688970PubMed
6,203,663Idiosyncratic reaction to bleomycin in an epithelial tumor.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6203663PubMed
6,153,937Lung damage from cytotoxic drugs.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6153937PubMed
3,552,281N-methyl antitumour agents. A distinct class of anticancer drugs?Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3552281PubMed
3,539,298Current approaches to the treatment of advanced-stage non-Hodgkin's lymphoma.CMAJ1987https://conductscience.org/library/papers/3539298PubMed
2,910,510Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2910510PubMed
2,793,382Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial.Invest New Drugs1989https://conductscience.org/library/papers/2793382PubMed
2,471,602Tallysomycin S10b--a phase I trial.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2471602PubMed
2,457,455HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/2457455PubMed

See all 30 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/61732

GET https://conductscience.org/api/papers/v1/61732/cited_by?page=2